Sprint Bioscience AB (SPRINT) — Cash Flow-to-Debt Ratio
Sprint Bioscience AB (SPRINT) has a Cash Flow-to-Debt Ratio of 6.63x as of December 2025, meaning its operating cash flow of Skr115.84 Million could theoretically repay 7% of its total liabilities (Skr17.48 Million) in one year. See SPRINT free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sprint Bioscience AB Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Sprint Bioscience AB across 14 annual periods. Also explore net asset growth rate of Sprint Bioscience AB to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sprint Bioscience AB (2012–2025)
Year-by-year debt coverage analysis for Sprint Bioscience AB. For market capitalisation and broader financial context, see Sprint Bioscience AB market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 4.78x | Skr83.53 Million | Skr17.48 Million | ▲ +770.6% |
| 2024 | -0.71x | Skr-23.36 Million | Skr32.78 Million | ▼ -207.8% |
| 2023 | 0.66x | Skr22.87 Million | Skr34.60 Million | ▲ +110.3% |
| 2022 | -6.40x | Skr-59.05 Million | Skr9.23 Million | ▼ -38.4% |
| 2021 | -4.62x | Skr-40.12 Million | Skr8.68 Million | ▼ -247.8% |
| 2020 | -1.33x | Skr-32.22 Million | Skr24.25 Million | ▲ +61.0% |
| 2019 | -3.40x | Skr-28.00 Million | Skr8.23 Million | ▼ -293.2% |
| 2018 | -0.87x | Skr-19.08 Million | Skr22.05 Million | ▲ +72.2% |
| 2017 | -3.12x | Skr-23.05 Million | Skr7.40 Million | ▼ -925.9% |
| 2016 | 0.38x | Skr7.93 Million | Skr21.03 Million | ▲ +1068.6% |
| 2015 | 0.03x | Skr833.54K | Skr25.81 Million | ▲ +101.4% |
| 2014 | -2.23x | Skr-10.76 Million | Skr4.83 Million | ▼ -156.8% |
| 2013 | -0.87x | Skr-3.57 Million | Skr4.11 Million | ▼ -21.3% |
| 2012 | -0.72x | Skr-2.29 Million | Skr3.20 Million | — |